Switzerland's Novocure Q3 revenue rises 16%, beats estimates
NVCR•Novocure's third-quarter revenue rose 16% year over year to $193.4 million, above the $182.23 million analyst estimate. The company raised its 2026 revenue and adjusted EBITDA guidance and said Optune Pax was approved in Japan for locally advanced pancreatic cancer.
1. Revenue and patient growth
Novocure reported third-quarter revenue of $193.4 million, up 16% year over year and above the $182.23 million consensus estimate. The company said global active patients grew 19%, driving the revenue increase, and reported a net loss of $10.44 million.
2. Higher 2026 guidance
Novocure raised its 2026 net revenue guidance to $736 million-$743 million from $710 million-$725 million. It lifted its adjusted EBITDA forecast to $24 million-$34 million from $0-$15 million and expects quarterly gross margins in the mid-to-high 70s percent range in 2026.
3. Japan approval
Optune Pax was approved in Japan for locally advanced pancreatic cancer. Novocure said it recognized $4.4 million in net revenue from one-time increases in claims approval rates in the United States and Germany.
